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During inﬂammation, leukocyte-derived eosinophil peroxidase catalyses the formation of hypobromous
acid, which can brominate tyrosine residues in proteins to form bromotyrosine. Since eosinophils are
involved in the pathogenesis of allergic reactions, such as asthma, urinary bromotyrosine level has been
used for the assessment of children with asthma. However, little is known about the metabolism and
disposition of bromotyrosine in vivo. The aim of this study was to identify the major urinary metabolites
formed during bromotyrosine metabolism and to develop mass spectrometric methods for their quan-
titation. Deuterium-labeled bromotyrosine was synthesized by deuterium exchange. [D3]bromotyrosine
(500 nmole) was injected intraperitoneally into Sprague-Dawley rats and urine was collected for 24 h in
a metabolic cage. 13C-labeled derivatives of bromotyrosine and its major urinary metabolite were syn-
thesized and used as internal standards for quantitation. Following solid phase extraction, urine samples
were derivatized to the pentaﬂuorobenzyl ester, and analyzed using isotope dilution gas chromatography
and negative-ion chemical ionization mass spectrometry. A novel brominated metabolite, 3-bromo-4-
hydroxyphenylacetic acid (bromo-HPA), was identiﬁed as the major brominated metabolite of bromo-
tyrosine. Bromo-HPA only accounted for 0.4370.04% of infused [D3]bromotyrosine and 0.1270.02% of
infused [D3]bromotyrosine was excreted in the urine unchanged. However, 1.3% (6.6671.33 nmole) of
infused [D3]bromotyrosine was excreted in the urine as the de-brominated metabolite,
[D3]4-hydroxyphenylacetic acid, which is also a urinary metabolite of tyrosine in mammals. We also
tested whether or not iodotyrosine dehalogenase can catalyse de-bromination of bromotyrosine and
showed that iodotyrosine dehalogenase is able to de-brominate free bromotyrosine in vitro. We iden-
tiﬁed bromo-HPA as the main brominated urinary metabolite of bromotyrosine in rats. However, de-
halogenation of bromotyrosine is the major metabolic pathway to eliminate free brominated tyrosine
in vivo.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Eosinophils play an important role in the mammalian immune
system during allergic reactions, as well as in immune responses
against extracellular parasites. Following activation, eosinophils
release effectors, such as cationic proteins and eosinophil perox-
idase, that lead to host defense and/or tissue damage [1]. Eosi-
nophil peroxidase is a halide peroxidase that preferentially uses
bromide to generate hypobromous acid, even at physiological
halide concentrations where chloride is almost 1000-fold greater
than bromide concentrations [1]. Hypobromous acid is a bromi-
nating agent that can brominate nucleophilic aromatic com-
pounds, such as tyrosine [2,3]. Wu et al., reported thatr Inc. This is an open access article
oyal Free Campus, University
W3 2PF, UK.3-bromotyrosine and 3,5-di-bromotyrosine are detectable fol-
lowing eosinophil peroxidase-induced protein oxidation [2].
Likewise, neutrophil-derived myeloperoxidase uses chloride, bro-
mide and nitrite ions to generate halogenating and nitrating
agents that lead to the formation of 3-chlorotyrosine, 3-bromo-
tyrosine and 3-nitrotyrosine [4–6]. Therefore, halogenated tyr-
osine residues are commonly used to quantify leukocyte-mediated
damage in diseased tissues [7,8]. However, one of the major
disadvantages of measuring bromotyrosine or chlorotyrosine is
that oxidized proteins undergo proteolysis, and the resulting free
halogenated amino acids are metabolized and excreted in the ur-
ine [9].
Since eosinophils play an important role in the pathogenesis of
allergic asthma, quantitation of urinary bromotyrosine levels has
been used as a non-invasive biomarker for the monitoring of
children with asthma [10–12]. Thus, Wedes et al. demonstrated
that urinary bromotyrosine levels predict the risk of future asthma
exacerbations in children [11]. Moreover, Cowan et al., haveunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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predict the responsiveness to inhaled corticosteroid therapy in
asthmatic patients [12]. Although urinary bromotyrosine mea-
surements have been used for the assessment of eosinophil acti-
vation, very little is known about the metabolism and disposition
of bromotyrosine in vivo. This is surprising, given the fact that
major urinary metabolites of chlorotyrosine and nitrotyrosine
have been identiﬁed [9,13,14] and their measurement has been
employed for assessment of systemic inﬂammation in vivo [15,16].
Thus, it is known that chlorotyrosine is metabolized to 3-chloro-4-
hydroxyphenylacetic acid (chloro-HPA) and 4-hydro-
xyphenylacetic acid (HPA), the major urinary metabolites of
chlorotyrosine in vivo [9]. We previously found that, following
infusion of deuterium-labeled chlorotyrosine, the urinary excre-
tion rate of deuterium-labeled chloro-HPA and HPA was 3.3- and
35.6-fold greater than the un-metabolized chlorotyrosine, re-
spectively [9]. Likewise, quantitation of the urinary metabolites of
bromotyrosine may provide a better, non-invasive assessment of
bromination reactions in vivo than the urinary concentration of
un-metabolized bromotyrosine. In the present study, we used
mass spectrometry in order to identify the major urinary meta-
bolites of bromotyrosine and di-bromotyrosine.2. Materials and methods
2.1. Chemicals
All chemicals were purchased from Sigma-Aldrich, unless sta-
ted otherwise. [13C9]Tyrosine, [D4]acetic acid, D2O, and deuterium
chloride (37% in D2O) were purchased from Cambridge Isotope
Laboratories (Andover, MA).
2.2. Animals
Male Sprague-Dawley rats (270–300 g) were obtained from the
Comparative Biology Unit at University College London. Animal
procedures were in accordance with the Home Ofﬁce, UK
guidelines.
2.3. Synthesis of deuterium-labeled compounds
[D3]Bromotyrosine was synthesized by deuterium exchange as
described [9,14], using authentic bromotyrosine as starting mate-
rial. In brief, 50 mg of bromotyrosine were dissolved in a mixture
of [D4]acetic acid and D2O, and the solvent was evaporated in a
stream of nitrogen at 90 °C. This procedure was repeated twice to
remove active protons. The resulting residue was dissolved in a
mixture of [D4]acetic acid, D2O and deuterium chloride. The so-
lution was sealed in an acid-digestion bomb and heated in an
autoclave at 190 °C for 8 h [9,14]. The resulting product wasTable 1
The mass balance of the derivatized authentic, 13C and deuterium-labeled compounds t
Compound Authentic
Tyrosine Tyrosine
407
3-Bromotyrosine Bromotyrosine
489
4-Hydroxyphenylacetic acid (HPA) HPA
331
3-Bromo-HPA Bromo-HPA
409
3,5-Di-bromo-HPA Di-bromo-HPA
489dissolved in 0.1% (v/v) triﬂuoroacetic acid (TFA)/water (adjusted to
pH 5.0 with ammonia solution) and extracted on a LC18 reverse-
phase column, pre-washed with 2 ml of methanol and 5 ml of 0.1%
(v/v) TFA/water (pH 5.0). The products were washed with water,
and the deuterated products eluted with 4 ml of 30 % (v/v) me-
thanol in water. The products were puriﬁed further by thin-layer
chromatography [14], and their concentrations determined against
known amounts of unlabeled standards by GC/MS (see below).
2.4. Synthesis of 13C-labeled internal standard for the measurement
of bromotyrosine, 4-hydroxyphenylacetic acid (HPA) and 3-bromo-4-
hydroxyphenylacetic acid (bromo-HPA)
[13C9]Bromotyrosine was synthesized by the reaction of
[13C9]tyrosine with hypobromous acid (HOBr) at room tempera-
ture for 1 h. HOBr was prepared freshly by adding HOCl to NaBr as
described [17]. The products were puriﬁed using LC18 solid phase
extraction, followed by HPLC. [13C8]4-hydroxyphenylacetic acid
(HPA) was synthesized following deamination and decarboxyla-
tion of [13C9]tyrosine, using Taiwan cobra venom as described
previously [14]. [13C8]3-Bromo-4-hydroxyphenylacetic acid (bro-
mo-HPA) was synthesized and puriﬁed by bromination of
[13C8]HPA in the same way as bromotyrosine, and the concentra-
tions of 13C-labeled standards determined against known amounts
of unlabeled standards by GC/MS.
2.5. Measurement of bromotyrosine and tyrosine by GC/MS
13C-Labeled internal standard (5 ng) was added to 20 ml of rat
urine and diluted to 1 ml of total volume with 0.1 % (v/v) TFA/
water (pH 5.0). The samples were extracted using LC18 reverse
phase column, as described above. Bromotyrosine and tyrosine
were derivatized with ethyl heptaﬂuorobutyrate and silylated with
tert-butyldimethylsilyl, as described [9,17,18]. Derivatized samples
were dried under nitrogen, and redissolved in 20 ml of n-undecane.
Samples were applied to a GC equipped with a 15-m DB-1701
(J&W Scientiﬁc, Folsom, CA) capillary column (0.25-mm internal
diameter, 0.25-mm ﬁlm thickness), interfaced with a mass spec-
trometer (Trio 1000; Fisons Instruments, Beverly, MA). The ion
source and interface temperatures were set at 200 and 320 °C,
respectively. Samples were analyzed in negative-ion chemical io-
nization mode with ammonia as the reagent gas, using 1 ml of each
sample for injection. The initial column temperature was main-
tained at 150 °C for 1 min increasing to 300 °C at 20 °C/min. Ions
were monitored at 489, 492, and 498 mass units for authentic, [D3]
and [13C9]bromotyrosine, respectively (Table 1). For measurement
of tyrosine, samples were monitored at 407, 410 and 415 m/z for
authentic, [D3]tyrosine and [13C9]tyrosine, respectively. Con-
centrations were calculated by ratio to known 13C9-labeled inter-
nal standards.hat were used for single-ion monitoring during mass spectrometry.
13C-labeled Deuterium-labeled
[13C9]Tyrosine [D3]Tyrosine
415 410
[13C9]Bromotyrosine [D3]Bromotyrosine
498 492
[13C8]HPA [D3]HPA
339 334
[13C8]Bromo-HPA [D3]Bromo-HPA
417 412
[13C8]Di-bromo-HPA Not used in this study
497
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13C-Labeled internal standard (5 ng) was added to 20 ml of rat
urine and diluted to 1 ml with 0.1 % (v/v) TFA/water (pH 5.0). The
samples were extracted using LC18 reverse-phase column as de-
scribed above. The samples were derivatized to the penta-
ﬂuorobenzyl ester by the addition of 20 ml of di-isopropyl ethyla-
mine in acetonitrile and 40 ml of 10 % (v/v) pentaﬂuorobenzyl
bromide in acetonitrile for 1 h at room temperature (21–23 °C),
dried under nitrogen, and redissolved in 20 ml of n-undecane for
GC/MS analysis [9,14]. The GC/MS set up was as described above,
and ions were monitored at 409, 412, and 417 mass units for au-
thentic, [D3] and [13C8]bromo-HPA, respectively, with single-ion
monitoring (Table 1). For measuring HPA, samples were monitored
at 331, 334, and 339 mass units for authentic, [D3] and [13C8]HPA,
respectively. The concentrations were calculated from the known
13C8-labeled internal standards.
2.7. Metabolism of di-bromotyrosine in vivo
A similar method used by Ohshima et al. [13] was used for
identiﬁcation of urinary metabolites of di-bromotyrosine. Male
Sprague-Dawley rats (n¼3 in each group) were given in-
traperitoneal injection of either di-bromotyrosine or tyrosine
(30 mmol). Urine was collected in metabolic cages for 24 h. Urine
samples were acidiﬁed to pH 1.0 with HCl and extracted with an
equivalent volume of ethyl acetate. The concentrated extracts were
derivatized to the pentaﬂuorobenzyl ester by the addition of 20 ml
of di-isopropyl ethylamine in acetonitrile and 40 ml of 10% (v/v)
pentaﬂuorobenzyl bromide in acetonitrile for 1 h at room tem-
perature (21–23 °C), dried under nitrogen, and re-dissolved in
20 ml of n-undecane for full scan GC/MS analysis [9].
2.8. Metabolism of [D3]bromotyrosine in vivo
Male Sprague-Dawley rats (n¼3 in each group) were given a
single intraperitoneal injection of [D3]bromotyrosine (0.50 mmol)
[9]. The animals were then transferred to standard metabolic ca-
ges, and urine samples were collected for 24 h. The levels of
deuterated bromotyrosine, tyrosine, bromo-HPA, and HPA were
measured in the collected urine samples, as described above.
2.9. De-bromination of [D3]bromotyrosine by cultured hepato-
blastoma (HepG2) cells
HepG2 cells (ECACC, Wiltshire, UK) were maintained in MEM
(minimum Eagle's medium) supplemented with 10% fetal calf
serum. Monolayer HepG2 cells were plated in 175 cm3 vented
tissue culture ﬂasks until 70% conﬂuent, when they were in-
cubated with [D3]bromotyrosine (ﬁnal concentration 25 mM). 24 h
after incubation with [D3]bromotyrosine, cells were washed two
times with PBS and were detached from the ﬂask using a cell
scraper. Detached cells were washed and re-suspended in 2 ml of
PBS. Cell suspensions were subjected to protein precipitation by
adding 1 ml of ice-cold chloroform/methanol (2:1, v/v) solution.
After centrifugation (1000 g for 20 min), protein precipitates
were washed with methanol and lyophilized under vacuum for
assessment of protein-bound [D3]bromotyrosine and [D3]tyrosine
as described [9,17,18]. In brief, 1–2 mg freeze-dried proteins were
hydrolyzed in alkaline condition (1 ml of 4 M NaOH for 16 h at
120 °C) in presence of 20 ng and 1 mg of [13C9]bromotyrosine and
[13C9]tyrosine, respectively, as internal standard. The samples were
extracted using LC18 and ENVþ (Jones Chromatography, UK) re-
verse phase columns. The samples were then derivatized with
ethyl heptaﬂuorobutyrate and silylated with tert-butyldi-
methylsilyl, and monitored for ion masses of 492, 498, 410, 415 for[D3]bromotyrosine, [13C9]bromotyrosine, [D3]tyrosine and
[13C9]tyrosine, respectively (Table 1) using negative-ion chemical
ionization GC/MS [9,17,18]. The experiment was repeated three
times. All data are expressed as mean7standard error.
2.10. Interaction of bromotyrosine and iodotyrosine dehalogenase
(DEHAL) in vitro
Iodotyrosine dehalogenase 1 (DEHAL1) was obtained from
HEK293 cells transfected with DEHAL1 cDNA, using a pcDNA3.1
expression vector [9,19]. To determine whether bromotyrosine, di-
bromotyrosine or bromo-HPA interact with iodotyrosine dehalo-
genase, deiodinase activity was measured based on radioiodide
formation from [125I]iodotyrosine. Incubation mixtures contained
[125I]iodotyrosine (∼100,000 cpm mixed with 0.1 μM unlabeled
iodotyrosine), DEHAL1 enzyme, and varying amounts of iodotyr-
osine, bromotyrosine, di-bromotyrosine, bromp-HPA and tyrosine
(0.01–100 μM ﬁnal concentration) in 100 μl of PBS containing
NADPH (100 μM), EDTA (2 mM), and dithiothreitol (10 mM) [9,19].
Mixtures were incubated in duplicate for 60 min at 37 °C, and the
reactions were stopped by addition of 0.9 ml of 10% acetic acid on
ice. The radioiodide in the mixture was separated from the re-
maining [125I]iodotyrosine with ion exchange chromatography on
Dowex columns. The columns were washed with 10 % acetic acid
and eluted with 8 ml of 1 mM ammonia solution. Blank incubations
without enzyme were used to correct for non-enzymatic deiodi-
nation. To determine whether bromotyrosine or di-bromotyrosine
could act as a substrate of DEHAL1, the brominated or iodinated
tyrosine derivatives (1 μM) were incubated with DEHAL1 in 100 μl
of PBS containing NADPH (100 μM), EDTA (2 mM), and dithio-
threitol (10 mM). Mixtures were then incubated in duplicate for
60 min at 37 °C, and the reaction was stopped by addition of 1 ml of
10 % acetic acid on ice. Substrate levels were measured using HPLC
as described [9]. Cell lysates from HEK293 cells transfected with
empty pcDNA3.1 plasmid were used as control. In experiments
where di-bromotyrosine, or di-iodotyrosine was used as substrate,
concentrations of mono-bromotyrosine and mono-iodotyrosine
were measured as a product of de-halogenation.3. Results
3.1. Structural conﬁrmation of bromotyrosine and tyrosine by GC/MS
For GC/MS analysis of bromotyrosine and tyrosine, the amine
group was derivatized with ethyl heptaﬂuorobutyrate, and the
hydroxyl and carboxylic groups were silylated with tert-butyldi-
methylsilyl and the products analyzed by negative-ion chemical
ionization mass spectrometry. Full scan mass spectra obtained for
these molecules are shown in Fig. 1. The major fragment ion of
tyrosine corresponds to loss of COO-tert-butyl-dimethylsilyl,
which results in a dominant ion at m/z 407 [17,18]. The major
fragment ion for bromotyrosine has an m/z of 489, which corres-
ponds to loss of tert-butyldimethylsilyl and bromide [17]. Fig. 1
also shows the mass spectrum of derivatized 13C-labeled tyrosine
and bromotyrosine. Full scan analysis of derivatized deuterated
bromotyrosine showed that the synthesized compound had a
dominant ion at m/z 492, which was 3 mass units heavier than the
authentic bromotyrosine, and which corresponded to
[D3]bromotyrosine.
3.2. Structural conﬁrmation of di-bromo-HPA, bromo-HPA and HPA
by GC/MS
The structures of the pentaﬂuorobenzyl ester derivatives of
HPA, bromo-HPA and di-bromo-HPA are shown in Fig. 2. Analysis
Bromotyrosine [13C9]Bromotyrosine
Tyrosine [13C9]Tyrosine
DMTBS
DMTBSOO
C3F7
O
NH
O
m/z 407
(-2 x HF)
Br
DMTBS
DMTBSOO
C3F7
O
NH
O
m/z 489
Fig. 1. Structures and spectra from negative-ion chemical ionization scans of the ethyl heptaﬂuoro and tert-butyldimethylsily derivatives of authentic and 13C-labeled
tyrosine (upper panel) and 3-bomotyrosine (lower panel).
HPA [13C8]HPA
[13C8]Bromo-HPA
[13C8]Di-bromo-HPADi-bromo-HPA
Bromo-HPA
PFB
O
PFB
O
O
Br
PFB
O
PFB
O
O
Br Br
PFB
O
PFB
O
O
m/z 331
m/z 409
m/z 365
m/z 489
m/z 445
Fig. 2. Structures and spectra from negative-ion chemical ionization scans of the pentaﬂuorobenzyl derivative of authentic and 13C-labeled 4-hydroxyphenylacetic acid (HPA,
upper panel), 3-bromo-4-hydroxyphenylacetic acid (bromo-HPA, middle panel) and 3,5-di-bromo-4-hydroxyphenylactic acid (di-bromo-HPA, lower panel).
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full scan mode showed that HPA has a dominant ion at m/z 331
(M-181), which is due to the loss of a pentaﬂuorobenzyl ester
group. As shown in Fig. 2, bromo-HPA had a dominant ion at m/z
409 (M-181, loss of one pentaﬂuorobenzyl ester group). Di-bromo-
HPA had a dominant ion at m/z 489 (M-181), which is also caused
by the loss of a pentaﬂuorobenzyl ester group (Fig. 2). On the basis
of these results, all further work was focused on developing a
method to quantitate di-bromo-HPA, bromo-HPA and HPA using
the pentaﬂuorobenzyl ester derivative with selective ion mon-
itoring at 489, 409 and 331 mass units for di-bromo-HPA, bromo-
HPA and HPA, respectively. Fig. 2 also shows the mass spectra of
derivatized 13C-labeled derivatives of HPA and brominated HPA. As
shown in this ﬁgure, the synthesized compounds had dominant
ions, which were 8 mass units heavier than the authenticBr
PFB
O
PFB
O
O
m/z 409
m/z 365
Fig. 3. Gas chromatogram of urine samples analyzed with full scan mass spectrometry
from rats given 3,5-di-bromotyrosine (A) showed two consistent additional peaks on the
spectra of these peaks are identical to those of the pentaﬂuorobenzyl derivatives of 3-brocompounds corresponding to [13C8]di-bromo-HPA,
[13C8]bromo-HPA and [13C8]HPA.
3.3. Metabolism of di-bromotyrosine and bromotyrosine
Analysis of urine extracts from rats given di-bromotyrosine
showed two main additional peaks on the GC, compared with
urine obtained from rats given tyrosine alone (Fig. 3A and B). Full
scan mass spectra of these two peaks are shown in Figs. 3C and 4D.
These peaks were identiﬁed as di-bromo-HPA (the peak with re-
tention time of 9.39 min) and bromo-HPA (the peak with retention
time of 8.51 min). In separate experiments, we incubated the urine
samples with alkaline phosphatase (from calf intestine, 300 U/ml)
and sulfatase (300 U/ml, from Helix pomatia) to break sulfate and
phosphate groups, in order to enhance derivatization of the*
**
Br Br
PFB
O
PFB
O
O
m/z 489
m/z 445
after derivatization with pentaﬂuorobenzyl bromide. The analysis of urine samples
chromatogram compared with urine samples of tyrosine treated rats (B). The mass
mo-4-hydroxyphenylactic acid (C) and 3,5-di-bromo-4-hydroxyphenylactic acid (D).
Bromo-HPA
[D3]bromo-HPA
[13C8]bromo-HPA
8.400 8.600 8.800
rt90
100
%
70
100
%
28
100
%
8.586 m/z: 409
8.591 m/z: 412
8.591 m/z: 417
Fig. 4. Chromatogram of a representative urine sample obtained from a rat injected
with [D3]bromotyrosine. Formation of deuterated 3-bromo-4-hydroxyphenylacetic
acid ([D3]bromo-HPA) represented as a distinguished peak that was detected with
m/z 412 (middle panel). The values of m/z 409 (lower panel) and m/z 417 (upper
panel) represent authentic bromo-HPA and 13C-labeled internal standard
respectively.
[13C9]Tyrosine
6.250 6.500 6.750 7.000
rt0
100
%
7
100
%
2
100
%
6.528 m/z: 407
6.523 m/z: 410
6.531 m/z: 415
[D3]Tyrosine
Tyrosine
Fig. 5. Chromatogram of the proteolyzed cell lysate after incubation of HepG2 cells
with [D3]bromotyrosine (25 mM). Incorporation of [D3]tyrosine in the cellular
proteins is represented as a peak that was detected with m/z 410. The values of m/z
407 and m/z 415 represent authentic tyrosine and 13C-labeled internal standard
respectively.
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phatase and sulfatase enhanced the appearance of bromo-HPA
peaks, we were unable to identify any other new metabolites
when the chromatograms of di-bromotyrosine and tyrosine trea-
ted rat urine samples were compared.
In further experiments, we injected rats with 0.5 mmole of
[D3]bromotyrosine and used GC/MS to quantify urinary con-
centrations of [D3]bromotyrosine, [D3]tyrosine, [D3]bromo-HPA
and [D3]HPA by isotope dilution mass spectrometry. As shown in
Fig. 4, a peak with m/z of 412 was detectable in the urine of
[D3]bromotyrosine treated rats, corresponding to the formation of
[D3]bromo-HPA. This peak was not detectable in normal rat urine
(data not shown). Urinary [D3]bromo-HPA was quantiﬁed using a
13C-labeled internal standard that we synthesized. [D3]bromo-HPA
accounted for 0.4370.04% of infused [D3]bromotyrosine.
0.1270.02% of infused [D3]bromotyrosine was excreted in the
urine unchanged. [D3]tyrosine was undetectable in rat urine
samples. However 1.3% (6.6671.33 nmole) of infused
[D3]bromotyrosine was excreted in the urine as the de-brominated
metabolite, [D3]HPA, which is the main urinary metabolite of
tyrosine in mammals, which suggests that dehalogenation of
bromotyrosine occurs in vivo ( Table 2).
3.4. De-bromination of [D3]bromotyrosine by cultured HepG2 cells
We incubated deuterium-labeled bromotyrosine with cultured
HepG2 cells and looked at incorporation of deuterated bromotyr-
osine ([D3]bromotyrosine) and tyrosine ([D3]tyrosine) into cellularTable 2
Urinary excretion of deuterated bromotyrosine, tyrosine, bromo-HPA and HPA after intr
[D3]Bromotyro
Total amounts (nmole) excreted in 24-h urine 0.6270.10
Molar percentage of the excreted metabolites in 24-h urine 0.1270.02%proteins. As shown in Fig. 5, we could detect deuterated tyrosine
(but not deuterated bromotyrosine) in the cell fraction obtained
from HepG2 cells following incubation with [D3]bromotyrosine.
This suggests that bromotyrosine is not incorporated directly into
proteins, but can be de-brominated to tyrosine, which is in-
corporated. Thus, using 13C-labeled tyrosine as internal standard,
we could show that 6.6870.52 nmole of [D3]tyrosine is detectable
in cellular proteins following incubation of the cells for 24 h with
250 nmoles of [D3]bromotyrosine (25 mM solution, total volume
10 ml).
3.5. Interaction of DEHAL1 and brominated tyrosine derivatives in
vitro
As shown in Fig. 6A, both bromotyrosine and di-bromotyrosine
could inhibit DEHAL1-induced deiodinase activity in a con-
centration-dependent manner. Neither tyrosine nor bromo-HPA
showed the ability to inhibit deiodination induced by DEHAL1. We
then tested whether or not bromotyrosine might serve as a sub-
strate for DEHAL1 dehalogenase. DEHAL1 converted 83% and 18%
of iodotyrosine and bromotyrosine, respectively (Fig. 6B). Likewise,
DEHAL1 converted 70% and 4% of di-iodotyrosine and di-aperitoneal injection of 500 nmole of [D3]bromotyrosine in rats.
sine [D3]Tyrosine [D3]Bromo-HPA [D3]HPA
Undetectable 2.1570.21 6.6671.33
Undetectable 0.4370.04% 1.3370.26%
Fig. 6. (A) The effect of di-bromotyrosine, bromotyrosine, bromo-HPA, iodotyr-
osine, and tyrosine on iodotyrosine dehalogenase 1 (DEHAL1)-induced deiodina-
tion of radiolabelled iodotyrosine. (B) The effect of DEHAL1 on dehalogenation of
iodotyrosine, di-iodotyrosine, bromotyrosine and di-bromotyrosine in the presence
of NADPH and dithiothreitol.
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iodotyrosine and di-bromotyrosine with DEHAL1 was associated
with formation of mono-iodotyrosine (7%) and mono-bromotyr-
osine (3%). No dehalogenation occurred when the substrates were
incubated with control cell lysates transfected with empty
pcDNA3.1 plasmid.4. Discussion
Eosinophil peroxidase is a haloperoxidase that preferentially
uses bromide over chloride for generating hypobromous acid to
kill extracellular parasites. Hypobromous acid can readily bromi-
nate biomolecules such as tyrosine and uracil to form 3-bromo-
tyrosine and 5-bromouracil [2,3].
Since eosinophil activation is involved in the pathogenesis of
eosinophilic asthma, recent studies have focused on measuring
urinary concentrations of bromotyrosine as a potential biomarker
for assessment of patients with asthma [10–11]. Although this
approach is interesting within the context of developing a non-
invasive biomarker for screening and monitoring of patients with
asthma, it is likely that bromotyrosine is metabolized in vivo and
the urinary level of un-metabolized bromotyrosine may reﬂect
only a small fraction of brominated tyrosine that is formed during
eosinophil activation. It is well known that tyrosine and its deri-
vatives such as nitrotyrosine and chlorotyrosine undergo deami-
nation and decarboxylation to form HPA, 3-nitro-HPA and
3-chloro-HPA [9,13,14]. In addition, we and others have also
shown that chlorotyrosine and iodotyrosine are readily de-halo-
genated in vivo [8,19,20]. In the present study, we observed twoextra peaks following the administration of a single dose of di-
bromotyrosine when compared with the urinary chromatograms
of tyrosine injected animals. The mass spectra of these two peaks
were compatible with di-bromo-HPA and mono-bromo-HPA
(Fig. 3). Both of these metabolites are deaminated and dec-
arboxylated metabolites (Fig. 7). Furthermore, formation of mono-
bromo-HPA indicates that de-bromination reaction also occurs
during metabolism of di-bromotyrosine in vivo. To make sure that
the formation of mono-bromotyrosine is not an artifact, we mea-
sured the purity of injected di-bromotyrosine and excluded the
possibility of contamination with mono-bromotyrosine (data not
shown).
To further conﬁrm these results we synthesized deuterium-la-
beled and 13C-labeled bromotyrosine and its urinary metabolites.
Since large doses of bromotyrosine may saturate the metabolic en-
zymes, we injected a low dose (500 nmole) of [D3]bromotyrosine and
measured urinary concentrations of [D3]bromo-HPA, [D3]HPA as well
as un-metabolized [D3]bromotyrosine. Our results conﬁrm the for-
mation of both brominated and de-brominated metabolites
([D3]bromo-HPA and [D3]HPA). We also demonstrated that the ur-
inary excretion rate of deuterium-labeled bromo-HPA and HPA were
3.6- and 10.7-fold greater than for un-metabolized bromotyrosine,
respectively. Thus, our studies conﬁrm that the urinary excretion of
bromo-HPA is markedly higher than that of un-metabolized bromo-
tyrosine, and bromo-HPA may therefore be a better marker for the
non-invasive assessment of bromotyrosine formation and thus eosi-
nophil activation, in vivo, compared with un-metabolized bromotyr-
osine. Recent reports, by Professor Hazen’s group, have also demon-
strated that urinary bromotyrosine has value in the prediction of
exacerbation as well as corticosteroid resistance in children with
asthma [11,12]. Future studies are required to compare the predictive
value of urinary bromo-HPA versus bromotyrosine in the assessment
and monitoring of patients with asthma. We also found that HPA is
the major urinary metabolite of bromotyrosine. However, this de-
brominated compound is not exclusively associated with bromotyr-
osine metabolism and HPA is a common end-product of tyrosine, and
chlorotyrosine metabolism [9]. Although increased urinary excretion
of HPA has been reported in a variety of medical conditions [21], in-
creased urinary HPA cannot be used to speciﬁcally assess either
bromination or chlorination reactions in vivo.
Amino acids have a large volume of distribution (Vd) in
the body and they can enter the cells and be used as the building
blocks for protein synthesis. Less than 2% of injected
[D3]bromotyrosine as its urinary metabolites was recovered over
the 24 h following its injection. This ﬁnding corroborates with the
large volume of distribution of bromotyrosine in vivo. However, we
did not know, whether or not, free bromotyrosine can be used for
cellular protein synthesis. Therefore, HepG2 cells were incubated
with deuterium labeled bromotyrosine and protein-bound
[D3]bromotyrosine and [D3]tyrosine in the cellular fractions were
measured 24 h after incubation with [D3]bromotyrosine. Although
no protein-bound [D3]bromotyrosine was found in the cell lysate,
we were able to detect [D3]tyrosine in the cell fraction which
corroborates with the de-bromination of bromotyrosine and in-
corporation of deuterium-labeled tyrosine in the cellular proteins.
We have previously reported similar ﬁndings after incubation of
cultured cells with labeled chlorotyrosine [9]. This indicates that
cellular de-halogenation is not restricted to de-chlorination and
de-iodination reactions [9,19,20]. We have previously ruled out
the role of cytochrome P450 de-chlorination of chlorotyrosine [9].
Although the metabolism of chlorotyrosine and bromotyrosine
seems to be similar, the formation and metabolism of these pro-
ducts could follow different kinetics [22–24]. In a previous report
we were unable to show a signiﬁcant de-chlorination of chlor-
otyrosine by DEHAL1 in vitro [9]. In present study we tested
whether or not bromotyrosine, di-bromotyrosine, or bromo-HPA
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Fig. 7. The metabolism of 3,5-di-bromotyrosine and 3-bromotyrosine in vivo. Both 3,5-di-bromotyrosine and 3-bromotyrosine can undergo deamination and decarbox-
ylation to form 3,5-di-bromo-4-hydroxyphenlacetic acid (3,5-di-bromo-HPA) and 3-bromo-4-hydroxyphenlacetic acid (3-bromo-HPA). In addition, both 3,5-di-bromotyr-
osine and 3-bromotyrosine undergo de-bromination to form de-brominated metabolites such as 4-hydroxypenylacetic acid (HPA).
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de-bromination of bromotyrosine and di-bromotyrosine in vitro.
This data corroborates with previous report by McTamney and
Rokita who showed that bromotyrosine is capable of oxidizing
reduced DEHAL1 under the same condition described for iodo-
tyrosine [23]. Our results also indicated that brominated tyrosine
(but not bromo-HPA) can inhibit deiodinase activity of DEHAL1 in
vitro. Our report indicates that DEHAL1 is also a de-brominase
enzyme and its activity is not restricted to de-iodination of iodo-
tyrosine, as typically described (i.e. iodotyrosine deiodinase). DE-
HAL1 is expressed in a variety of tissues (including the thyroid
gland, liver and kidney) and plays an important role in recycling of
iodide in mammalian tissues [19,20]. Although a dramatic reduc-
tion in DEHAL1 activity is known to cause congenital hypothyr-
oidism [19], in silico studies have shown that partial inhibition of
DEHAL1 activity may lead to abnormal thyroid function [25]. In-
hibition of iodotyrosine deiodinase activity by bromotyrosine (a
by-product of leukocyte activation) may contribute to thyroid ab-
normalities that are associated with systemic inﬂammation [25].
However, further investigations are required to examine the role of
bromotyrosine in pathogenesis of thyroid disorders.
Bromine is mostly present in animals as ionic bromide and,
apart from its role in eosinophils, it serves an essential function in
the formation of sulﬁlimine crosslinks in collagen type IV [26].
Since this process requires the formation of hypobromous acid,
bromination of the extracellular matrix might be considered as a
by-product in the development of essential crosslinks of the ex-
tracellular matrix. Likewise, Baldus et al. reported that transcytosis
of myeloperoxidase confers the speciﬁcity to modiﬁcation of the
tyrosine-residues of vascular matrix proteins during systemicinﬂammation [11]. Therefore, it is likely that a de-bromination or
de-chlorination mechanism may play a protective role during
tissue regeneration following inﬂammation. We have previously
demonstrated that rat liver homogenates can de-chlorinate pro-
tein-bound chlorotyrosine in vitro [9]. Kamisaki et al. also reported
a “denitrase” activity that catalyzed de-nitration of protein-bound
nitrotyrosine in vitro [27]. We did not study the de-bromination of
protein-bound bromotyrosine in the present study. This can be
further investigated, along with the mechanism of de-chlorination
and de-nitration in future.
One of the limitations of our study is that we did not in-
vestigate the mechanism of bromo-HPA formation in our experi-
mental model. It is not known, whether or not, bromo-HPA is
exclusively derived from the metabolism of bromotyrosine. Fu
et al., demonstrated that reaction of free chlorotyrosine with HOCl
may lead to the formation of chloro-hydroxyphenylacetaldehyde,
which is structurally similar to (but distinct from) chloro-HPA [28].
Such reaction may occur for bromotyrosine as well, and needs to
be explored in future investigations. Likewise, we previously re-
ported that nitro-HPA is not exclusively derived from nitrotyrosine
metabolism, and it is mainly formed by nitration of HPA in both
humans and rats [14,29]. To determine whether or not bromo-HPA
could be formed by endogenous bromination of HPA in healthy
rats, deuterium-labeled HPA ([D6]HPA) was synthesized and in-
jected into healthy rats as described [14]. The formation of deut-
erated bromo-HPA was then monitored in urine samples. We were
unable to detect [D5]bromo-HPA in rat urine following in-
traperitoneal injection of [D6]HPA in healthy rats (data not shown).
This may indicate that bromination of endogenous HPA does not
occur abundantly in vivo. Another limitation of the present study is
A.R. Mani et al. / Free Radical Biology and Medicine 90 (2016) 243–251 251that we did not test whether or not bromo-HPA can undergo de-
bromination in vivo. However, our in vitro study showed that un-
like bromotyrosine, incubation of bromo-HPA with either DEHAL1
or rat liver homogenates was not associated with formation of de-
brominated products (data not shown).
In conclusion, we identiﬁed di-bromo-HPA and bromo-HPA as
the main brominated urinary metabolites of di-bromotyrosine and
bromotyrosine in rats. However, de-halogenation of bromotyr-
osine also occurs during metabolism of bromotyrosine in vivo.Conﬂict of interest
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